CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma
Ralph Schmid
Molecular Cancer Therapeutics, 2019
View PDFchevron_right
Abrogating G2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma
T. Giordano
Cancer Biology & Therapy, 2014
View PDFchevron_right
Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the dl922-947 Oncolytic Virus in Malignant Mesothelioma Cell Lines
Giuseppe Portella
International Journal of Molecular Sciences, 2020
View PDFchevron_right
Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight
Ralph Schmid
Frontiers in Oncology, 2020
View PDFchevron_right
Targeting Wee1 for the treatment of pediatric high-grade gliomas
Daphne Haas-kogan
Neuro-Oncology, 2014
View PDFchevron_right
Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets
Oluf Dimitri Røe
Lung Cancer, 2010
View PDFchevron_right
Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy
S. Fawell, Stuart Shumway
Molecular cancer therapeutics, 2013
View PDFchevron_right
Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells
Lilli Bay
Cancers, 2021
View PDFchevron_right
In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma
Angela van Tilborg, Dirk Geerts
Cancer cell, 2010
View PDFchevron_right
Identification of wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies
Kristen Cowens
Leukemia, 2014
View PDFchevron_right
Synergy of WEE1 and mTOR inhibition in mutant KRAS-driven lung cancers
Geoffrey Shapiro
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017
View PDFchevron_right
EIF4G1 and RAN as Possible Drivers for Malignant Pleural Mesothelioma
LOREDANA MIGLIORE
International Journal of Molecular Sciences, 2020
View PDFchevron_right
Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells
Bruce Aronow
Cell Reports, 2015
View PDFchevron_right
Molecular Targets in Malignant Pleural Mesothelioma Treatment
Giulia Pasello
Current Drug Targets, 2009
View PDFchevron_right
56: Multiple RTK targeting as a therapeutic option in malignant pleural mesothelioma
Kieran Crosbie Staunton
Lung Cancer, 2017
View PDFchevron_right
The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas
Journal of Cancer Metastasis and Treatment, Michael Offin
Journal of Cancer Metastasis and Treatment, 2023
View PDFchevron_right
Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS
Sang-we Kim
Translational oncology, 2018
View PDFchevron_right
KAP1 is a new non-genetic vulnerability of malignant pleural mesothelioma (MPM)
FRANCESCA REGGIANI
NAR Cancer
View PDFchevron_right
Therapies currently in Phase II trials for malignant pleural mesothelioma
Daniela D Tavian
Expert Opinion on Investigational Drugs, 2013
View PDFchevron_right
Genomic mapping identifies multiple therapeutic pathways in malignant mesothelioma
Deborah Morris-Rosendahl
View PDFchevron_right
Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity
Norbert Berndt
ACS chemical biology, 2017
View PDFchevron_right
UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma
Lisa Uechi
Journal of Thoracic Oncology, 2020
View PDFchevron_right
The efficacy of the Wee1 inhibitor MK-1775 combined with temozolomide is limited by heterogeneous distribution across the blood-brain barrier in glioblastoma
Stuart Shumway, Jenny Pokorny
Clinical cancer research : an official journal of the American Association for Cancer Research, 2015
View PDFchevron_right
A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma
H. Brahmbhatt
American journal of respiratory and critical care medicine, 2015
View PDFchevron_right
Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis
Joanna Pearce
Journal of Clinical Investigation
View PDFchevron_right
Tumour suppressive effects of WEE1 gene silencing in breast cancer cells
Ahmad Hosseini
Asian Pacific journal of cancer prevention : APJCP, 2014
View PDFchevron_right
Molecular Pharmacology of Malignant Pleural Mesothelioma: Challenges and Perspectives from Preclinical and Clinical Studies
Antonio Daga, Federica Barbieri
View PDFchevron_right
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma
Antonio Daga
British journal of pharmacology, 2012
View PDFchevron_right
CARP-1 Functional Mimetics Are a Novel Class of Small Molecule Inhibitors of Malignant Pleural Mesothelioma Cells
Magesh Muthu, Abdelkader Ashour
PLoS ONE, 2014
View PDFchevron_right
Knockdown of COPA, Identified by Loss-of-Function Screen, Induces Apoptosis and Suppresses Tumor Growth in Mesothelioma Mouse Model
Masakazu Kohda
Genomics, 2010
View PDFchevron_right
Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition
Stuart Shumway, Nathan Miselis, Andrew Bloecher
Cancer Cell International, 2012
View PDFchevron_right
The Pattern of RNA Editing Changes in Pleural Mesothelioma upon Epithelial-Mesenchymal Transition
Didier Jean
International Journal of Molecular Sciences, 2023
View PDFchevron_right
Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach
Kamal Mohammed
American journal of cancer research, 2012
View PDFchevron_right